Biorce to Host AI for Clinical Trials Conference The End. in Barcelona on October 15

Biorce to host the third edition of The End., the AI for clinical trials conference, taking place this fall in one of Europe’s fastest-growing biotech ecosystems, Barcelona.

Barcelona - [September 10, 2026] - Biorce will bring together global leaders in clinical innovation, artificial intelligence, biotechnology, and pharma for the third edition of The End. of clinical trials as we knew them, taking place on October 15 at Espai Diagonal, Barcelona’s newest landmark venue.

The End. is a high-trust convergence of pharma pioneers, biotech founders, researchers, regulators, and investors shaping the future of clinical research. The one-day experience will feature visionary keynotes and strategic networking focused on how AI is transforming clinical trial development. Following the success of the previous edition in Boston earlier this year, The End. Barcelona will provide a unique platform for the advancement of AI-powered clinical development. Taking place in the Catalan capital, one of Europe’s fastest-growing biotech ecosystems, The End. Barcelona will convene leaders from pharma, biotech, CROs, investment firms, regulatory bodies, and research organizations to explore the next era of clinical development.

The End. Barcelona will take place one day after SCOPE Europe 2026 and will bring together 250 experts. Seats are limited and registration is required. The AI for clinical trials conference will be held in the heart of Barcelona at Espai Diagonal (Avenida Diagonal 458), a distinctive new landmark venue that opened its doors in May 2026.

Speakers include Craig Lipset, Managing Partner at Clinical Innovation Partners, Dr. Jonathan Crowther, Head, Operational Design Center at Merck Healthcare KgaA, and Zak Smith, Assistant Director, Data Sciences & Analytics at Tufts CSDD. For more information, visit https://www.biorce.com/the-end

About Biorce

Biorce is an AI healthtech startup, building defensible AI solutions for clinical trial development. Its platform, Aika, is a continuous intelligent layer, from protocol decision to regulatory submission, enabling fewer amendments and a dramatic reduction of cost and time.